Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic

27.02.2004


Scientists report that an unlikely molecule has emerged as an attractive target for development of therapeutics aimed at a diverse spectrum of tumors, including some malignancies that are resistant to conventional therapies. Two studies published online in Cancer Cell demonstrate that the insulin-like growth factor 1 receptor (IGF-1R) is required for the survival of tumor cells and provide direct evidence that inhibition of IGF-R1 using selective small molecules represents a novel potential anticancer treatment.



Extensive studies have suggested that IGF-1R plays a role in the development of human cancers. IGF-1R is present in a broad range of tumor types including multiple myeloma, lymphoma, leukemia, and breast, lung, prostate, and colon cancers. However, IGF-1R has not been viewed as a likely target for cancer therapeutics because many normal cells also contain the protein. Research scientists from Dana-Farber Cancer Institute in Boston and Novartis Institutes for Biomedical Research Basel demonstrate that IGF-1R inhibition using a variety of methods had potent antitumor effects against many types of cancer cells grown in the laboratory, including cells that are resistant to conventional cancer therapeutics.

Molecular analyses demonstrated that IGF-1R inhibition impacts multiple intracellular signals related to cell proliferation or tumor development and provides possible mechanisms to explain how IGF-1R inhibition can make tumor cells more sensitive to conventional chemotherapy or other anticancer agents. Perhaps most significantly, IGF-1R suppresses tumor growth, prolongs survival, and enhances the antitumor effect of chemotherapy in clinically relevant mouse models of multiple myeloma and other hematological malignancies. The researchers also identify two small molecules that are selective inhibitors of IGF-1R and are active anticancer agents against tumors that contain IGF-1R. These small molecules represent highly attractive potential therapeutics.


According to study author Dr. Constantine S. Mitsiades of Dana-Farber, "These results suggest that IGF-1R function is critically required for tumor cell survival, but dispensable for survival of normal cells in adult animals. The preclinical activity of IGF-1R inhibitors against a broad spectrum of tumor cells and, importantly, their ability to sensitize tumor cells to a wide range of anticancer agents, highlight the major role of IGF-1R signaling for human malignant cells, and suggest that the molecular pathway of IGF-1R is an attractive potential target for development of anticancer therapeutics."


Constantine S. Mitsiades, Nicholas S. Mitsiades, Ciaran J. McMullan, Vassiliki Poulaki, Reshma Shringarpure, Masaharu Akiyama, Teru Hideshima, Dharminder Chauhan, Marie Joseph, Towia A. Libermann, Carlos Garcia-Echeverria, Mark A. Pearson, Francesco Hofmann, Kenneth C. Anderson Andrew L. Kung: "Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies and solid tumors"

Carlos García-Echeverría, Mark A. Pearson, Andreas Marti, Thomas Meyer, Juergen Mestan, Johann Zimmermann, Jiaping Gao, Josef Brueggen, Hans-Georg Capraro, Robert Cozens, Dean B. Evans, Doriano Fabbro, Pascal Furet, Diana Graus Porta, Janis Liebetanz, Georg Martiny-Baron, Stephan Ruetz, Francesco Hofmann: "In vivo anti-tumour activity of NVP-AEW541 - A novel, potent and selective inhibitor of the IGF-IR kinase"

Published online 26 February 2004; Cancer Cell, Volume 5, Number 3, March 2004.

Heidi Hardman | EurekAlert!
Further information:
http://www.cell.com/

More articles from Health and Medicine:

nachricht Light beam replaces blood test during heart surgery
28.02.2017 | University of Central Florida

nachricht Cells adapt ultra-rapidly to zero gravity
28.02.2017 | Universität Zürich

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Safe glide at total engine failure with ELA-inside

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded after a glide flight with an Airbus A320 in ditching on the Hudson River. All 155 people on board were saved.

On January 15, 2009, Chesley B. Sullenberger was celebrated world-wide: after the two engines had failed due to bird strike, he and his flight crew succeeded...

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Existence of a new quasiparticle demonstrated

28.02.2017 | Materials Sciences

Sustainable ceramics without a kiln

28.02.2017 | Materials Sciences

Biofuel produced by microalgae

28.02.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>